The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10820 malaria professionals are enjoying the free benefits of MalariaWorld today

4-aminoquinolines

NOT Open Access | Does hydroxychloroquine still have any role in the COVID-19 pandemic

March 17, 2021 - 16:58 -- NOT Open Access
Author(s): 
Schilling WH, White NJ
Reference: 
Expert Opin Pharmacother. 2021 Mar 16:1-10

The 4-aminoquinolines, chloroquine, and hydroxychloroquine have been used for over 70 years for malaria and rheumatological conditions, respectively. Their broad-spectrum antiviral activity, excellent safety profile, tolerability, low cost, and ready availability made them prime repurposing therapeutic candidates at the beginning of the COVID-19 pandemic.

No evidence that chloroquine or hydroxychloroquine induce hemolysis in G6PD deficiency

November 4, 2020 - 16:10 -- Open Access
Author(s): 
Schilling WHK, Bancone G, White NJ
Reference: 
Blood Cells Mol Dis. 2020 Nov;85:102484

Hydroxychloroquine and chloroquine have come under intense scrutiny over the past six months as they have been proposed as treatments for COVID-19. It is widely quoted and stated that the 4-aminoquinolines chloroquine and hydroxychloroquine cause oxidant hemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficiency, yet there is no convincing evidence for this claim, and there is substantial evidence against it. X-linked G6PD deficiency is the most common human enzymopathy.

Subscribe to RSS - 4-aminoquinolines